Promitil
Financiado
Promitil a new smart nanomedicine for cancer chemo radiotherapy.
There were over 18M new cases of cancer worldwide in 2018, out of which about 3.7M were in Europe. To treat cancer, radiotherapy is increasingly used in combination with chemotherapy. Chemo-radiotherapy is a non-invasive approach...
There were over 18M new cases of cancer worldwide in 2018, out of which about 3.7M were in Europe. To treat cancer, radiotherapy is increasingly used in combination with chemotherapy. Chemo-radiotherapy is a non-invasive approach for cancer local control, given within a reduced period time and with potential for complete cure of cancer. The key to enabling the full potential of chemo-radiotherapy depends on radio-sensitization, which means the degree of effectiveness of the anti-cancer agents used for chemotherapy that make tumour cell more sensitive to radiation therapy. However, radio-sensitizers, like Mitomycin-C (MMC), still need to be significantly improved to achieve a more effective and safe treatment of patients.
LipoMedix has developed a novel nanomedicine (Promitil® ) for chemo-radiotherapy. It is a liposome formulation of a Mitomycin-C Lipid-based (MLP) prodrug of the anticancer agent MMC. Promitil® enables efficient delivery of MLP with rapid activation in tumour tissue, yet with improved safety profile because it becomes active only upon radiation. This results in a higher and safer radio-sensitization effect.
LipoMedix is an Israeli pharma SME founded in 2011. Its team has been involved for more than 20 years in cancer drugs and therapies, and now its mission is deliver to a novel, efficient, and side-effect free liposome prodrug to improve patients’ quality of life, healthcare outcomes and reduce the economic healthcare stress of chemo-radiotherapy.
The SME-I Phase 1 project perfectly suits the innovation’s current stage of development and overall business strategy allowing LipoMedix to check final specifications of Promitil®, establish sound business development and gain partners necessary for the Phase II study.
ver más
Duración del proyecto: 4 meses
Fecha Inicio: 2019-07-09
Fecha Fin: 2019-11-30
Fecha Fin: 2019-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
LIPOMEDIX PHARMACEUTICALS LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
494.96K€ |
Participante